HIGHLIGHTS Q1-2017 REPORT

Strong results of the Phase 2a study for SER150 in Diabetic Nephropathy was announced:

  • Serodus is planning to publish the details of the findings from the study later in 2017
  • Results are currently being presented to potential partners, investors and scientific advisors
  • Serodus is preparing for a pre-IND meeting

Serodus was delisted from Oslo Stock Exchange and is now a private company.

The company completed the subscription of a convertible loan of 25 MNOK Serodus is currently focussing all resources on SER150 for the treatment of patients with diabetic nephropathy.

Close Menu